Seeking Alpha

DURECT strikes deal with Impax to get Eladur back into development

  • Impax Labs (IPXL -1.7%) and DURECT (DRRX +5.6%) announce a development and commercialization agreement for the PHN patch, Eladur.
  • IPXL is paying $2M upfront for exclusive worldwide rights.
  • Additional payments could reach $61M depending upon "the achievement of predefined development and commercialization milestones."
  • DRRX also gets royalties assuming the patch reaches the market.
  • IPXL is controlling and funding development. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs